$INVA News

Innoviva Inc (NASDAQ:INVA): A Decent Value Play with Strong Fundamentals

INNOVIVA INC (NASDAQ:INVA): A Strong Growth Stock Poised for a Technical Breakout

Innoviva Inc (NASDAQ:INVA): A GARP Standout with 470% EPS Growth and a P/E of Just 6.05

Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets

Innoviva Specialty Therapeutics Inks Agreement With Dr. Reddy's Laboratories To Develop, Commercialize XACDURO To Treat Bacterial Pneumonia

Innoviva, Inc. (INVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

HC Wainwright & Co. Reiterates Buy on Innoviva, Maintains $46 Price Target

BTIG Reiterates Buy on Innoviva, Maintains $42 Price Target

INNOVIVA INC (NASDAQ:INVA) Scores as a Value Stock with Strong Fundamentals

Is Innoviva (INVA) Pricing Look Compelling After Recent Share Price Softness?

Innoviva, Inc. (INVA) Draws Bullish View from Cantor on Recurring Royalty Strength

BTIG Maintains Buy on Innoviva, Raises Price Target to $42

Innoviva (INVA) Tops Q1 Earnings Estimates

Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress

Innoviva Q1 EPS $2.22 Beats $0.36 Estimate, Sales $97.994M Miss $101.555M Estimate

3 Bargain-Cheap Small Caps Worth a Second Look

Beacon Biosignals Upsizes Series B Financing to Over $97 Million

Innoviva Inc (NASDAQ:INVA) Screened as a Top Value Stock with Strong Fundamentals

Analysts See This Pharma Stock Surging 60%; Eyes Fresh Entry

Is It Time To Revisit Innoviva (INVA) After Strong Multi Year Share Price Gains